,
Erik Vollebregt
Some time ago I wrote about the proposed ENVI resolution that the the EU Parliament’s ENVI committee adopted in reaction to the PIP breast implants scandal in the EU. At that time…
,
Erik Vollebregt
I read an interesting article in the Economist’s Technology Quarterly of June 2nd-8th of 2012, p. 17-18, on open source medical devices software. Let me summarise for you: the article starts by…
,
Erik Vollebregt
The Advocate General of the EU Court presented his conclusion today in one of the three medical devices borderline cases currently pending at the EU Court, C-219/11 Brain Products vs BioSemi. The…
,
Erik Vollebregt
The European Parliament’s ENVI Committee (Committee on the Environment, Public Health and Food Safety) has added to the political pressure on the European Commission that is currently working on the proposal of…
,
Erik Vollebregt
Interesting developments after the joint plan for action that Commissioner Dalli sent to the member states in the beginning of February this year urging them to step up market surveillance in order to…
,
Karin Verzijden
The seminar addressed current and future EU legal and regulatory developments relevant to cell-based therapies. In particular, the seminar focused on how to choose and support the right regulatory pathway for a…
,
Carine van den Brink
The seminar addressed current and future EU legal and regulatory developments relevant to cell-based therapies. In particular, the seminar focused on how to choose and support the right regulatory pathway for a…
,
Erik Vollebregt
I hope you won’t mind me imposing on you with some more self promotion – it’s for your own good as this is about saving you money, both in the short run…
,
Erik Vollebregt
Whenever Ms Minor from DG SANCO speaks at an event, everyone in the medical devices industry listens, hoping for new elements about where the Commission is going with the recast, review or…